Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer94
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery91
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)89
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)82
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes78
Redefining readmissions in gynecologic cancer: readmissions resulting in hospital-to-hospice transitions may represent high value care77
Sentinel lymph node procedures in endometrial cancer: an international multicenter experience75
Stage IV gynecologic cancers patients who subsequently died from disease: lessons learned from their health care journey74
The impact of the SARS-COV2 pandemic on the delivery of chemotherapy for gynecologic cancer at a tertiary care institution in the United States epicenter72
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)67
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne67
Outcomes of splenectomy during primary cytoreductive surgery in ovarian cancer58
Perioperative outcomes in obese women with uterine cancer56
Neoadjuvant chemotherapy with interval debulking surgery versus chemotherapy alone for advanced epithelial ovarian cancer56
Recurrent ovarian cancer: maintenance treatment with PARP inhibitors in clinical practice55
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)55
Prognostic factors of survival in women with recurrent platinum-resistant epithelial ovarian cancer (1171)54
Predictors of long-term response in prospective phase II trial of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer (1247)52
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 120352
TOGETHER Care: PatienT-tailOred GynEcologic Oncology posT discHargE caRe (290)51
Hot or not: defining trophoblast PD-L1 expression and lymphohistiocytic density in gestational trophoblastic neoplasia51
Impact of surgeon type and rurality on treatment and survival of ovarian cancer patients49
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)48
Diversifying clinical trials: Does presentation at gynecologic oncology tumor board increase equitable access to clinical trials for Black and LatinX patients? (2205)47
Clinical outcomes and cost associated with HRD biomarker guided first line maintenance therapy in advanced ovarian cancer47
Clinical impact of low-volume lymph node metastases in early- stage cervical cancer: A comprehensive meta-analysis (504)45
Mitigating disparity? Recurrence rates and palliative care referrals by race and ethnicity across a large urban health system (514)44
Comparison of solid tumor mutations under the targeted agent and profiling utilization registry (TAPUR) study: how do gynecologic cancers compare with others?44
Determining the optimal adjuvant therapy strategy in uterine leiomyosarcoma44
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)44
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma (529)43
Disparities in access to high volume surgeons within high volume hospitals for hysterectomy43
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)42
Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer42
Impact of increased cycles of neoadjuvant chemotherapy on interval debulking surgery outcomes (541)42
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)40
Creation of a surgical service line to treat patients with recurrent gynecologic cancer with curative intent: Complex oncologic multidisciplinary pelvic surgery (COMPS) (559)40
Pattern of recurrence and survival: Comparative analysis of robotic radical hysterectomy with uterine manipulator versus without uterine manipulator and or vaginal cerclage in treatment of stage IB ce40
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? – A geospatial analysis (2127)39
Assessing somatic mutations in matched biospecimens from patients with serous ovarian cancer39
Impact of venous thromboembolism on timing and outcomes of interval debulking surgery among patients treated with neoadjuvant chemotherapy for advanced ovarian cancer (370)39
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)39
Prediction of ovarian cancer with deep machine-learning and alternative splicing (2167)39
0.19992303848267